Smith & Nephew 

$29.99
429
-$0.13-0.43% Friday 20:00

統計

當日最高
30.05
當日最低
29.78
52週最高
31.72
52週最低
21.53
成交量
382,559
平均成交量
757,800
市值
13.45B
市盈率
44.07
股息收益率
2.5%
股息
0.75

即將到來

股息

2.5%股息收益率
10年增長
2.96%
5年增長率
0.6%
3年增長率
N/A
1年增長率
N/A

收益

1Aug預期
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0
16.07
32.13
48.2
預期每股收益
0.3928
實際每股收益
0.376

人們還關注

此列表基於在 Stock Events 上關注 SNN 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

0$平均價格目標
最高估價為 $0。
來自過去 6 個月內的 1 個評級。這不是投資建議。
買入
100%
持有
0%
賣出
0%

關於

Health Technology
Medical Specialties
Manufacturing
Surgical Appliance and Supplies Manufacturing
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Show more...
首席執行官
Roland Diggelmann
員工
18000
國家
US
ISIN
US83175M2052

上市公司